Popular Filters
Trials for Liver Cancer Patients
Chemotherapy
Drug Combination for Liver Cancer
Recruiting1 awardPhase 1
Gainesville, Florida
This trial aims to test a new combination of three drugs for treating liver cancer. The study will determine safe doses of the drugs and evaluate their effectiveness in improving patient outcomes compared to the current standard treatment.
Checkpoint Inhibitor
Durvalumab + Tremelimumab for Liver Cancer
Recruiting1 awardPhase 2
Toronto, Ontario
This trial is testing a new cancer treatment that consists of two drugs, Durvalumab and Tremelimumab. The treatment is given before surgery to remove the tumor and then given again after surgery. The trial is testing if this treatment is safe and if it changes the tumor microenvironment. 28 patients are expected to enroll at three sites.
Monoclonal Antibodies
Atezolizumab + Bevacizumab +/− SRF388 for Liver Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial tests SRF388 with atezolizumab and bevacizumab in patients with advanced liver cancer. The treatment aims to enhance immune response and block blood supply to tumors. Atezolizumab and bevacizumab have become the standard of care for advanced hepatocellular carcinoma, replacing sorafenib which was the standard for over ten years.
Trials for HCC Patients
Monoclonal Antibodies
Atezolizumab + Bevacizumab +/- Tiragolumab for Liver Cancer
Recruiting1 awardPhase 3
Baltimore, Maryland
This trial is testing a combination of three drugs—tiragolumab, atezolizumab, and bevacizumab—to treat advanced liver cancer that cannot be removed by surgery. These drugs help the immune system fight cancer and cut off the tumor's blood supply. The goal is to see if this combination is safe and effective for these patients.
Angiogenesis Inhibitor
Triple-Drug Combo for Liver Cancer
Recruiting0 awardsPhase 1 & 2
Los Angeles, California
This trial will compare the safety and effectiveness of a three-drug combo of nivolumab, relatlimab, and bevacizumab versus a two-drug combo of just nivolumab and bevacizumab in people with HCC that has not yet been treated.
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Trials for Metastatic Patients
Monoclonal Antibodies
Atezolizumab + Bevacizumab +/- Tiragolumab for Liver Cancer
Recruiting1 awardPhase 3
Baltimore, Maryland
This trial is testing a combination of three drugs—tiragolumab, atezolizumab, and bevacizumab—to treat advanced liver cancer that cannot be removed by surgery. These drugs help the immune system fight cancer and cut off the tumor's blood supply. The goal is to see if this combination is safe and effective for these patients.
Angiogenesis Inhibitor
Triple-Drug Combo for Liver Cancer
Recruiting0 awardsPhase 1 & 2
Los Angeles, California
This trial will compare the safety and effectiveness of a three-drug combo of nivolumab, relatlimab, and bevacizumab versus a two-drug combo of just nivolumab and bevacizumab in people with HCC that has not yet been treated.
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Monoclonal Antibodies
Atezolizumab + Bevacizumab +/− SRF388 for Liver Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial tests SRF388 with atezolizumab and bevacizumab in patients with advanced liver cancer. The treatment aims to enhance immune response and block blood supply to tumors. Atezolizumab and bevacizumab have become the standard of care for advanced hepatocellular carcinoma, replacing sorafenib which was the standard for over ten years.
Immunotherapy
INCA 0186 Combination Therapy for Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing a new drug called INCA00186, alone or with other drugs, in patients with advanced head and neck or gastrointestinal cancers that have CD8 T-cells. The treatment uses immunotherapy to help the immune system attack cancer cells.
Phase 3 Trials
Monoclonal Antibodies
Atezolizumab + Bevacizumab +/- Tiragolumab for Liver Cancer
Recruiting1 awardPhase 3
Baltimore, Maryland
This trial is testing a combination of three drugs—tiragolumab, atezolizumab, and bevacizumab—to treat advanced liver cancer that cannot be removed by surgery. These drugs help the immune system fight cancer and cut off the tumor's blood supply. The goal is to see if this combination is safe and effective for these patients.
Checkpoint Inhibitor
Regorafenib + Pembrolizumab vs. Loco-Regional Therapy for Liver Cancer
Recruiting2 awardsPhase 3
Santa Monica, California
This trial compares a drug combination (Regorafenib and Pembrolizumab) with localized treatments for liver cancer. It targets patients with intermediate-stage liver cancer that can't be cured with surgery. The drug combination works by stopping cancer growth and boosting the immune system, while the localized treatments directly target the liver cancer.
Statin
Simvastatin for Liver Cirrhosis
Recruiting1 awardPhase 3
San Francisco, California
This trial tests if simvastatin can prevent serious liver problems in U.S. Veterans with early-stage liver damage. Simvastatin not only lowers cholesterol but also helps protect the liver from further damage and reduces the risk of severe liver issues. Statins, including simvastatin, have been increasingly recognized for their potential benefits in treating chronic liver diseases, including cirrhosis, by reducing portal pressure and protecting against liver damage.
Trials With No Placebo
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Checkpoint Inhibitor
Regorafenib + Pembrolizumab vs. Loco-Regional Therapy for Liver Cancer
Recruiting2 awardsPhase 3
Santa Monica, California
This trial compares a drug combination (Regorafenib and Pembrolizumab) with localized treatments for liver cancer. It targets patients with intermediate-stage liver cancer that can't be cured with surgery. The drug combination works by stopping cancer growth and boosting the immune system, while the localized treatments directly target the liver cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.